{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,21]],"date-time":"2025-11-21T17:29:21Z","timestamp":1763746161571},"reference-count":43,"publisher":"Wiley","issue":"12","license":[{"start":{"date-parts":[[2002,12,12]],"date-time":"2002-12-12T00:00:00Z","timestamp":1039651200000},"content-version":"vor","delay-in-days":11,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Arthritis &amp; Rheumatism"],"published-print":{"date-parts":[[2002,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Objective<\/jats:title><jats:p>Hepatitis C virus (HCV)\u2013related vasculitis may involve multiple organs, including the skin, kidneys, and nervous system, and may be life\u2010threatening. Although HCV is increasingly recognized as a cause of systemic vasculitis, limited data are available regarding the optimal treatment of this potentially serious condition. Therefore, we retrospectively analyzed the response to treatment in patients with chronic hepatitis C complicated by systemic vasculitis who had received antiviral therapy with interferon\u2010\u03b1 (IFN\u03b1) and ribavirin.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>This retrospective study included 27 patients with systemic vasculitis and chronic HCV infection. Each patient had received treatment with IFN\u03b1 and ribavirin for at least 6 months. The response to antiviral treatment was analyzed by comparing clinical, immunologic, and virologic data at the time of entry and during followup. Clinical response was defined according to the evolution of weight, arthralgia, nervous system, renal system, and cutaneous involvement. The virologic and immunologic responses were defined by the absence of HCV RNA and the absence of cryoglobulinemia, respectively, both 6 months after stopping antiviral therapy and at the end of followup.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Patients received IFN\u03b1 for a mean \u00b1 SD of 20 \u00b1 14 months and ribavirin (at a mean \u00b1 SD dosage of 895 \u00b1 250 mg\/day) for 14 \u00b1 12 months. Other treatments included low\u2010dose corticosteroids and plasma exchange. After a mean \u00b1 SD followup of 57 \u00b1 29 months, 25 of 27 patients are alive and are being followed up as outpatients. Because of the heterogeneity of anti\u2010HCV treatments received, the main results were stratified according to patients with 6 months of followup after stopping antiviral treatment (group 1, n = 14) and those who were still undergoing antiviral therapy at the time of analysis (group 2, n = 13). Nine patients in group 1 had a sustained virologic response and were clinical and immunologic complete responders. Four patients in group 1 were virologic nonresponders, and 3 of these patients had partial clinical and immunologic responses. Overall, 10 patients in group 1 had a complete clinical and immunologic response of their vasculitis (all 9 of the sustained virologic responders and 1 of the 5 patients who remained viremic). At the end of followup, 7 patients in group 2 were negative for HCV RNA; 6 were complete clinical responders. Among the other 6 patients in group 2, who had persistent viremia, 4 had a partial clinical response. Among the patients in group 1, HCV RNA was more often undetectable and genotype 1 was less frequent in complete clinical responders compared with partial\/nonresponders. Age, sex, clinical vasculitic involvement, mean duration or total cumulative dose of IFN\u03b1 or ribavirin, and use of steroids or plasmapheresis did not differ significantly according to clinical response.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Treatment with IFN\u03b1 and ribavirin can achieve a complete clinical response in most patients with HCV\u2010related systemic vasculitis. Complete clinical response correlates with the eradication of HCV.<\/jats:p><\/jats:sec>","DOI":"10.1002\/art.10699","type":"journal-article","created":{"date-parts":[[2002,12,16]],"date-time":"2002-12-16T13:50:56Z","timestamp":1040046656000},"page":"3317-3326","source":"Crossref","is-referenced-by-count":153,"title":["Interferon\u2010\u03b1 and ribavirin treatment in patients with hepatitis C virus\u2013related systemic vasculitis"],"prefix":"10.1002","volume":"46","author":[{"given":"Patrice","family":"Cacoub","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Olivier","family":"Lidove","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thierry","family":"Maisonobe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pierre","family":"Duhaut","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vincent","family":"Thibault","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pascale","family":"Ghillani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert P.","family":"Myers","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jean Marc","family":"Leger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J\u00e9r\u00f4me","family":"Servan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jean\u2010Charles","family":"Piette","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2002,12,12]]},"reference":[{"key":"e_1_2_5_2_2","doi-asserted-by":"publisher","DOI":"10.1016\/0002-9343(67)90144-1"},{"key":"e_1_2_5_3_2","doi-asserted-by":"publisher","DOI":"10.1016\/0002-9343(78)90533-8"},{"key":"e_1_2_5_4_2","doi-asserted-by":"publisher","DOI":"10.1002\/1529-0131(200103)44:3<666::AID-ANR116>3.0.CO;2-A"},{"key":"e_1_2_5_5_2","doi-asserted-by":"publisher","DOI":"10.1002\/art.1780370205"},{"key":"e_1_2_5_6_2","doi-asserted-by":"publisher","DOI":"10.1093\/clinids\/20.4.1010"},{"key":"e_1_2_5_7_2","doi-asserted-by":"publisher","DOI":"10.1097\/00005792-199509000-00002"},{"key":"e_1_2_5_8_2","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1016\/S0889-857X(21)00479-8","article-title":"Polyarteritis nodosa, microscopic polyangiitis, and Churg\u2010Strauss syndrome: clinical aspects and treatment","volume":"21","author":"Lhote F","year":"1995","journal-title":"Rheum Dis Clin North Am"},{"key":"e_1_2_5_9_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM200107053450107"},{"key":"e_1_2_5_10_2","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-122-3-199502010-00002"},{"key":"e_1_2_5_11_2","doi-asserted-by":"publisher","DOI":"10.1002\/art.10107"},{"key":"e_1_2_5_12_2","doi-asserted-by":"publisher","DOI":"10.1097\/00005792-200001000-00005"},{"key":"e_1_2_5_13_2","doi-asserted-by":"publisher","DOI":"10.1002\/1529-0131(199910)42:10<2204::AID-ANR24>3.0.CO;2-D"},{"key":"e_1_2_5_14_2","doi-asserted-by":"publisher","DOI":"10.1002\/art.1780341221"},{"key":"e_1_2_5_15_2","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-117-7-573"},{"key":"e_1_2_5_16_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF00945029"},{"key":"e_1_2_5_17_2","doi-asserted-by":"publisher","DOI":"10.1016\/0002-9343(94)90132-5"},{"key":"e_1_2_5_18_2","doi-asserted-by":"publisher","DOI":"10.1002\/1529-0131(199912)42:12<2507::AID-ANR2>3.0.CO;2-#"},{"key":"e_1_2_5_19_2","first-page":"109","article-title":"Systemic vasculitis in patients with hepatitis C","volume":"28","author":"Cacoub P","year":"2001","journal-title":"J Rheumatol"},{"key":"e_1_2_5_20_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199403173301104"},{"key":"e_1_2_5_21_2","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1182\/blood.V81.5.1132.1132","article-title":"Interferon\u2010alpha in mixed cryoglobulinemia patients: a randomized, crossover\u2010controlled trial","volume":"81","author":"Ferri C","year":"1993","journal-title":"Blood"},{"key":"e_1_2_5_22_2","doi-asserted-by":"crossref","first-page":"3336","DOI":"10.1182\/blood.V84.10.3336.3336","article-title":"Natural interferon\u2010alpha versus its combination with 6\u2010methyl\u2010prednisolone in the therapy of type II mixed cryoglobulinemia: a long\u2010term, randomized, controlled study","volume":"84","author":"Dammaco F","year":"1994","journal-title":"Blood"},{"key":"e_1_2_5_23_2","doi-asserted-by":"crossref","first-page":"3865","DOI":"10.1182\/blood.V90.10.3865","article-title":"Predictors of long\u2010term response to high\u2010dose interferon therapy in type II cryoglobulinemia associated with hepatitis C virus","volume":"90","author":"Casato M","year":"1997","journal-title":"Blood"},{"key":"e_1_2_5_24_2","first-page":"1115","article-title":"Ribavirin in hepatitis C related cryoglobulinemia","volume":"25","author":"Durand JM","year":"1998","journal-title":"J Rheumatol"},{"key":"e_1_2_5_25_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(98)07124-4"},{"key":"e_1_2_5_26_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199811193392101"},{"key":"e_1_2_5_27_2","first-page":"2172","article-title":"Treatment of refractory, symptomatic, hepatitis C virus related mixed cryoglobulinemia with ribavirin and interferon\u2010alpha","volume":"27","author":"Zuckerman E","year":"2000","journal-title":"J Rheumatol"},{"key":"e_1_2_5_28_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199711203372106"},{"key":"e_1_2_5_29_2","doi-asserted-by":"publisher","DOI":"10.1002\/art.1780330805"},{"key":"e_1_2_5_30_2","doi-asserted-by":"publisher","DOI":"10.1016\/0002-9343(80)90390-3"},{"key":"e_1_2_5_31_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0168-8278(95)80002-6"},{"key":"e_1_2_5_32_2","doi-asserted-by":"publisher","DOI":"10.1093\/clinchem\/38.6.798"},{"key":"e_1_2_5_33_2","doi-asserted-by":"publisher","DOI":"10.1016\/0002-9343(74)90852-3"},{"key":"e_1_2_5_34_2","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp.60.6.661"},{"key":"e_1_2_5_35_2","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1212\/WNL.41.5.617","article-title":"Research criteria for diagnosis of chronic inflammatory demyelinating polyneuropathy (CIDP): report from an ad hoc subcommittee of the American Academy of Neurology AIDS Task Force","volume":"41","year":"1991","journal-title":"Neurology"},{"key":"e_1_2_5_36_2","first-page":"91","volume-title":"Guide to clinical neurology","author":"Hauw JJ","year":"1995"},{"key":"e_1_2_5_37_2","doi-asserted-by":"publisher","DOI":"10.1002\/hep.1840010511"},{"key":"e_1_2_5_38_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(01)06102-5"},{"key":"e_1_2_5_39_2","first-page":"2466","article-title":"Long term efficacy of interferon alpha for extrahepatic disease associated with hepatitis C virus infection","volume":"28","author":"Naarendorp M","year":"2001","journal-title":"J Rheumatol"},{"key":"e_1_2_5_40_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2893.1998.00099.x"},{"key":"e_1_2_5_41_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2249.2002.01728.x"},{"key":"e_1_2_5_42_2","first-page":"403","article-title":"Cryoglobulin\u00e9mie et h\u00e9patite C: aggravation de la neuropathie p\u00e9riph\u00e9rique apr\u00e8s prise d'interf\u00e9ron alpha","volume":"23","author":"Lidove O","year":"1999","journal-title":"Gastroenterol Clin Biol"},{"key":"e_1_2_5_43_2","doi-asserted-by":"publisher","DOI":"10.1001\/archneur.1997.00550190093020"},{"key":"e_1_2_5_44_2","doi-asserted-by":"publisher","DOI":"10.1002\/1529-0131(199905)42:5<1051::AID-ANR26>3.0.CO;2-Q"}],"container-title":["Arthritis &amp; Rheumatism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fart.10699","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/art.10699","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,23]],"date-time":"2023-11-23T15:09:32Z","timestamp":1700752172000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/art.10699"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2002,12]]},"references-count":43,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2002,12]]}},"alternative-id":["10.1002\/art.10699"],"URL":"https:\/\/doi.org\/10.1002\/art.10699","archive":["Portico"],"relation":{},"ISSN":["0004-3591","1529-0131"],"issn-type":[{"value":"0004-3591","type":"print"},{"value":"1529-0131","type":"electronic"}],"subject":[],"published":{"date-parts":[[2002,12]]}}}